Cabot Oil & Gas (NYSE:COG)- Short Call at News Buzzer: Prima Biomed Ltd. (NASDAQ:PBMD)

Several matter pinch shares of Cabot Oil & Gas Corporation (NYSE:COG) [Trend Analysis], as shares moving up 2.73% to $23.36 with a share volume of 12.93 Million. Cabot Oil & Gas Corporation (COG) revealed that the Federal Energy Regulatory Commission issued its final Environmental Impact Statement for Williams Partners’ (WPZ) Atlantic Sunrise project. The issuance of the final EIS is a key step toward the FERC’s final decision on the project, which is expected in early 2017.

Following the receipt of all necessary regulatory approvals, Williams Partners anticipates beginning construction in mid-2017, allowing for a full in-service of the project in mid-2018.In addition to previously reported gas sale and purchase contracts related to Cabot’s 850,000 MMBtu per day of transportation capacity on the Atlantic Sunrise project, Cabot also declared the execution of a new definitive gas sale and purchase contract with an undisclosed company. Under the terms of this new contract, the Company has agreed to sell an additional 150,000 MMBtu per day of natural gas for a term of three years commencing on the full in-service of the Atlantic Sunrise project.

The stock is going forward its 52-week low with 57.56% and moving down from its 52-week high price with -12.56%. To have technical analysis views, liquidity ratio of a company was calculated 3.30 as evaluated with its debt to equity ratio of 0.53. The float short ratio was 5.05%, as compared to sentiment indicator; Short Ratio was 3.27.

Prima Biomed Ltd. (NASDAQ:PBMD) [Trend Analysis] luring active investment momentum, shares a loss -6.40% to $2.34. Prima BioMed Ltd (PBMD) reported that it has developed a new early stage product candidate, a humanised IgG4 monoclonal antibody to be known as IMP761. This antibody, developed at the Company’s laboratory in Châtenay-Malabry south of Paris, is believed to be the first agonist antibody of LAG-3.

Dr. Frédéric Triebel said, “Even though IMP761 is an early stage product, we are very excited to have developed what we believe is the first ever agonist of LAG-3. Until now, therapeutic antibodies with agonistic properties have not been described for any of the three major immune checkpoints, CTLA-4, PD-1 or LAG-3. IMP761 promises the first opportunity for fine tuning of the immune response to an immune checkpoint target. This singular biological activity of IMP761 could benefit sufferers of certain autoimmune diseases by temporarily switching off activated LAG-3+T cells that are damaging tissue or creating inflammatory responses.” The total volume of 166528 shares held in the session was surprisingly higher than its average volume of 154.64 shares. While take a short look on price to sales ratio, that was 125.98.


About Gerard Bergeron

Gerard Bergeron covers Bio-pharmacy or healthcare sector Press Releases news updates. He has extensive three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a Reply

Your email address will not be published. Required fields are marked *